Premium
Hypoxia‐inducible factor‐1 as a therapeutic target in cancer
Author(s) -
Tang CeenMing,
Yu Jun
Publication year - 2013
Publication title -
journal of gastroenterology and hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.214
H-Index - 130
eISSN - 1440-1746
pISSN - 0815-9319
DOI - 10.1111/jgh.12038
Subject(s) - medicine , hypoxia (environmental) , angiogenesis , metastasis , transcription factor , hypoxia inducible factor 1 , hif1a , cancer research , chemotherapy , cancer , hypoxia inducible factors , cancer cell , bioinformatics , gene , oncology , pharmacology , biology , genetics , chemistry , organic chemistry , oxygen
Abstract Hypoxia‐inducible factor‐1 ( HIF ‐1) is a transcription factor that immortalizes tumors by inducing key genes in cancer biology, including angiogenesis, glycolysis, invasion, and metastasis. Overexpression of HIF ‐1α is thus associated with resistance to cancer chemotherapy and increased patient mortality in several cancer phenotypes. In the present review, we summarize the role of intratumoral hypoxia and bioactive lipids in enhancing HIF ‐1 activity, critically discussing the potential for HIF ‐1α inhibitors in cancer chemotherapy. Considering preclinical studies, HIF ‐1 inhibitors appear to have antitumor effects and thus represent a novel therapeutic strategy.